Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Silence Therapeutics ( (SLN) ).
On December 15, 2025, Silence Therapeutics announced the departure of Craig Tooman as CEO and Board member, effective December 14, 2025. Iain Ross, Chairman of the Board, has been appointed as interim principal executive officer, while James Ede-Golightly has rejoined the Board as a director. These leadership changes reflect the company’s ongoing commitment to advancing its commercial and scientific pipeline, with the company in strong financial and operational health.
The most recent analyst rating on (SLN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The overall score is driven by technical analysis and corporate events, which show positive momentum and strategic progress. However, financial performance and valuation are significant concerns due to profitability challenges and negative equity.
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company focused on developing novel siRNA therapies. Utilizing its mRNAi GOLD platform, the company aims to target and silence disease-associated genes, particularly in the liver, addressing high unmet medical needs in cardiovascular disease, hematology, and rare diseases.
Average Trading Volume: 198,478
Technical Sentiment Signal: Sell
Current Market Cap: $298.5M
For an in-depth examination of SLN stock, go to TipRanks’ Overview page.